# Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL

> **NCT05252403** · PHASE2 · UNKNOWN · sponsor: **Fondazione Matilde Tettamanti Menotti De Marchi Onlus** · enrollment: 35 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **GENETIC:** PTG-CARCIK-CD19

## Key facts

- **NCT ID:** NCT05252403
- **Lead sponsor:** Fondazione Matilde Tettamanti Menotti De Marchi Onlus
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-01
- **Primary completion:** 2024-12
- **Final completion:** 2025-03
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05252403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05252403, "Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05252403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*